- Home
- ALXO vs YOSH Comparison
ALXO vs YOSH Comparison
Compare ALXO & YOSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- YOSH
- Stock Information
- Founded
- ALXO 2015
- YOSH 2016
- Country
- ALXO United States
- YOSH United States
- Employees
- ALXO N/A
- YOSH N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- YOSH Restaurants
- Sector
- ALXO Health Care
- YOSH Consumer Discretionary
- Exchange
- ALXO Nasdaq
- YOSH Nasdaq
- Market Cap
- ALXO 24.0M
- YOSH 23.7M
- IPO Year
- ALXO 2020
- YOSH 2022
- Fundamental
- Price
- ALXO $0.48
- YOSH $12.12
- Analyst Decision
- ALXO Strong Buy
- YOSH
- Analyst Count
- ALXO 6
- YOSH 0
- Target Price
- ALXO $3.30
- YOSH N/A
- AVG Volume (30 Days)
- ALXO 397.6K
- YOSH 6.3K
- Earning Date
- ALXO 08-07-2025
- YOSH 08-18-2025
- Dividend Yield
- ALXO N/A
- YOSH N/A
- EPS Growth
- ALXO N/A
- YOSH N/A
- EPS
- ALXO N/A
- YOSH N/A
- Revenue
- ALXO N/A
- YOSH $13,539,317.00
- Revenue This Year
- ALXO N/A
- YOSH N/A
- Revenue Next Year
- ALXO N/A
- YOSH N/A
- P/E Ratio
- ALXO N/A
- YOSH N/A
- Revenue Growth
- ALXO N/A
- YOSH 41.82
- 52 Week Low
- ALXO $0.41
- YOSH $2.71
- 52 Week High
- ALXO $8.78
- YOSH $22.50
- Technical
- Relative Strength Index (RSI)
- ALXO 44.63
- YOSH 41.42
- Support Level
- ALXO $0.48
- YOSH $12.96
- Resistance Level
- ALXO $0.59
- YOSH $13.96
- Average True Range (ATR)
- ALXO 0.05
- YOSH 0.98
- MACD
- ALXO -0.00
- YOSH -0.18
- Stochastic Oscillator
- ALXO 8.75
- YOSH 15.91
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About YOSH Yoshiharu Global Co.
Yoshiharu Global Co is a restaurant operator. The company has one reportable segment, consisting of operating its stores. Yoshiharu serves the perfect, ideal ramen, as well as offers customers a wide variety of sushi, bento menus, and other favorite Japanese cuisines. It owns and operates restaurant stores.